reason report
bottom line recent host ceo toni hunt global head
ir sondra newman seri investor meet continu
believ lead innov tool biolog drug
product deliv conserv mid-teen organ
revenu growth long term reach revenu
today main takeaway meet
includ lead innov bioprocess tool
market continu maintain organ growth
long term set signific beneficiari gene
therapi market growth current rev integr
sale team build-out progress nice set strong
beyond remain key part strategi find
right asset paramount new product includ tfdf next-
gen flowvp product key driver next month
remain op pt
lead innov highli recur spec market
serv highli sticki spec d-in market bioprocess
scale process develop estim
direct product line chromatographi filtrat see
robust adopt custom seek innov solut address
squeez timelin tight cost control product growth also
support shift direct sell rep
field scale commerci infrastructur secular tailwind
increas mab approv emerg biolog drug categori
fuel growth gene therapi custom grow rapidli
repres sale like go higher time
 commerci integr underway revenu like
build time revamp sale team
roughli seven rep increas one salesperson pre-acquisit
integr progress well recal expect
deliv pro forma rev time sale rep
believ room signific upsid drive adopt
technolog sale cycl long proven
acceler top-lin growth acquir asset month
post close believ differ next-gen flowvp
product allow real-tim feedback manufactur also help
adopt believ growth like inflect
 remain key part growth strategi go forward
execut five major deal sinc spent cash
stock complet transact manag expect could
pursu deal everi month constraint find right
asset paramount manag look differenti
technolog carv nich marketplac
aspect optim
life scienc tool diagnost
ev sale multipl
revenu
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu thousand ep non-gaap adjust
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
repligen us lead innov tool biomolecular drug product
conserv expect exhibit organ mid-teen revenu growth longer term deliv
today view uniqu asset life scienc tool
space given serv one sticki specd-in market biomolecular drug
manufactur innov tool deliv averag market growth
bioprocess sector grow fastest among peer group bioprocess
compani given high growth product portfolio increas level diversif across
busi come contrast year compani deriv sale
oem busi protein ligand
serv market compani estim approach set
shape outlook profil growth compani top sell drug
antibody-bas humira opdivo believ monoclon antibodi maintain
larg market share given efficaci specif drug continu play role
scale process develop therapeut product addit fast grow
area includ gene therapi continu augment growth revenu
gene therapi today pois go higher longer term
rgen outlook view abil acquir innov technolog
recent acquisit technolog estim revenu deal make
lot sens us given tech product differenti natur high growth revenu abil
integr across downstream process accret natur
innov player protein measur space expect gener
revenu acquisit bound help acceler long-term outlook compani
import ingredi success continu rgen manag includ
ceo toni hunt continu execut except well compani deliv
except strong quarter expect deliv y/i growth year ceo hunt
long-stand experi bioprocess busi start appli biosystem
provid foresight key busi trend shape industri
increasingli complex biolog therapi come market remain confid
continu deliv strong growth near term prospect deliv market
growth rate long run
manag meet drive increas convict growth
recent host manag includ ceo toni hunt sondra newman
global head ir seri investor meet came away view
continu deliv strongli despit alreadi deliv remark growth year
continu maintain strong foothold bioproduct market differenti
product introduct strateg
far banner year organ revenu growth guid end
rang direct product line chromatographi filtrat set deliv
close organ growth year addit compani enter new vertic
acquisit april despit difficult comp
bp headwind oem protein came away increasingli confid
deliv revenu growth lt growth rang addit setup
cover bioprocess industri trend make success acquisit new
product fast-grow gene therapi market among other discuss
overal key takeaway meet includ
mid-teen long-term grower lead innov ls tool biolog
drug product includ cell gene therapi carv market posit
biomolecular product base investor meet expect continu
grow mid-teen sustain number think like conserv
continu benefit robust growth gene therapi market revenu
import growth driver compani longer term allogen cell
gene therapi come market
 integr progress well month post deal bolster sale team
vs sale rep bound acceler revenu growth differenti
technolog product
 remain key part growth strategi longer term manag remain
disciplin pick right asset technolog differenti presenc
bioprocess vs research enhanc growth profil compani
new product includ tfdf tangenti depth filtrat next-gen vpe
key driver growth next month
oem/protein segment experi headwind ge
transit offset emerg product partnership ligand
direct product chromatographi filtrat continu steadi growth
direct sell approach drive faster adopt product
remain lead innov bioproduct space
rgen differenti product filtrat chromatographi process analyt
continu drive organ growth longer term view repligen well-posit
direct product line address two grow trend bioproduct continu
manufactur single-us technolog posit power organ growth
chromatographi filtrat far current product set
manag believ address roughli chromatographi
becom market leader single-us pre-pack column estim
market share maintain share filtrat market leader
upstream perfus take share downstream ultrafiltration/diafiltr uf/df market
growth driven increas biolog drug approv emerg new drug
categori includ biosimilar gene therapi product introduct
hope address larger percentag global bioproduct
figur repligen product specif address market across product
gene therapi market posit develop recent quarter
could signific upsid longer term
gene therapi current repres overal revenu like goe higher
time ceo toni hunt bullish gene therapi prospect come year rgen
opu pre-pack column high demand gene therapi manufactur first half
gene therapi custom account opu revenu filtrat rgen
hollow fiber product perform well upstream downstream applic flat
sheet cassett busi also see nice adopt downstream applic
ls tool manufactur benefit unexpect resurg gene
therapi market mani still calibr big market seen
tmo acquisit brammer lead viral vector manufactur
nc recent purchas paragon lead contract develop
manufactur organ cdmo see robust demand gene therapi manufactur
servic race build capac brammer custom like see
continu growth op add capac brammer lead viral vector busi
base market pall see compound-annual-growth-rate gene therapi demand robust
biopharma budget alloc invest gene therapi fact fda believ
gene therapi drug approv year link
figur total gene therapi develop increas preclin
 acquisit integr go acceler sale bound
boost sale team revamp budget expect strong
perform recal repligen acquir estim revenu
 rgen first foray process analyt area high demand biolog
product grow compound-annual-growth-rate expect deliv pro
forma revenu meet ceo hunt explain due dilig
delight learn grow revenu compound-annual-growth-rate one
salesperson spoke volum differenti natur technolog recent month
build commerci infrastructur sale peopl
busi across us eu apac although sale cycl long
replac custom exist technolog proven acceler top-lin
growth acquir asset month post close believ differ
expect signific sale acceler month time rep fulli
product standpoint expect updat next-gen flowvp
product time tri integr exist downstream product
miniatur technolog make compliant manufactur regul
direct product line chromatographi filtrat continu
grown direct product line organ expect
momentum continu ceo toni hunt indic organ growth direct product line
continu grow compound-annual-growth-rate despit strong prior year comp head
opu revenu growth impress meet manag indic opu
volum gone expect column
demand caus manag expand opu manufactur capac next two
year four addit suit waltham nine addit suit manag
note new competit entrant pre-pack column space far ge
expect continu pack ge-own resin filtrat perform
balanc across portfolio spectrum product proconnex krosflo tff system
atf altern tangenti system flat sheet cassett atf system
reson custom manag note platform
product manufactur process allow benefit futur molecul
produc manufactur final manag pleas new structur
commerci team base end market upstream downstream rather
specif product line led collabor team increas cross-
sell recal scale commerci infrastructur significantli peopl
today number peopl field expand vastli rep today
expect continu add sale personnel busi scale bolster call point
within exist chromatographi filtrat franchis well build newer product
 remain part growth strategi
manag continu execut drive top line maintain disciplin
acquir differenti technolog execut five major deal sinc
spent cash stock complet deal manag would prefer deal
everi month constraint find right asset ceo hunt look
differenti technolog carv nich marketplac
addit optim target someth ideal fix under-staf
sale team oper issu case compani sale
person manag saw opportun acquir differenti technolog scale
infrastructur ideal lead adopt revenu growth subsequ
year manag continu look compani power technolog market
multipl higher given demand bioprocess tool compani market
manag believ analyt area includ protein measur space
appeal beyond core chroma filtrat franchis
new product go focu month manag
new product tfdf next-gen flowvp aid revenu growth next
year major part rgen success introduct new technolog
marketplac led strong adopt built brand recognit
innov front tfdf tangenti depth filtrat product line tfdf industri
first innov harvest clarif oper upstream process combin
centrifug depth filtrat step tfdf fed batch process
still make vast major market accord manag time ceo
hunt believ tfdf larg atf product perfus manufactur note
adopt cycl bioproduct industri take time product cycl elong
year versu sequenc yr mass spec year lead slower
uptak stay power revenu new tfdf product like
coupl million doubl follow year next-gen flowvp
product improv in-lin protein measur product manufactur integr
process allow real-tim monitor current in-lin flowvp product
make tech overal revenu manag hope next-gen product
ge protein transit pressur organ growth year manag
work off-set purolit navigo partnership
ge headwind well known like partial off-set strong partnership repligen
manufactur protein ligand crucial monoclon antibodi mab manufactur
process howev somewhat flat busi recent year concentr
larg custom includ manag explain ge bring
roughli protein purchas hous next year lead
headwind bp organ growth new purchas amount continu end
ge option extend agreement ligand
product off-set impact manag establish partnership two compani
purolit navigo protein develop new product space manag spoke
posit purolit partnership manag expect new product
introduc market shortli growth factor busi continu steadi
grower offset ge headwind
pt move higher peer group multipl confid healthi
premium peer current trade roughli ev sale premium
mid larg cap peer life scienc tool lst diagnost dx med-tech space
includ surpris premium
highli attract end market grow high singl digit reimburs risk
mani year runway scarciti valu associ exposur bioprocess
industri eu-bas sartoriu pure play highli recur cash flow due
specd natur bioprocess equip beat rais stori
recent quarter deliv revenu growth well expect initi guidanc
org revenue growth today guidanc stand org growth
reason believ deserv healthi premium peer pt base
ev sale revenu estim
primari risk price target includ slowdown global drug demand biolog could caus
downsid risk forecast slowdown biolog demand due lack drug molecul pipelin could result
lower revenu rel estim furthermor restrict global budget biopharma subsequ
cdmo could result shift focu strategi growth could increas oper risk declin
government spend toward biolog research could risk downsid forecast growth
biopharma declin pose greatest risk revenu declin biopharma fund could highli impact
revenu given third revenu lever biopharma industri slowdown biopharma fund would
result reduc fund drug includ biolog drive demand rgen product lower biomolecul
forecast ramp drug market mid-teen estim hing prolifer
drive use rgen bioprocess equip reagent character molecul
emerg market competit could pose risk rgen revenu competit asian market could drive
local manufactur choos local product drive overal revenu lower geopolit risk
emerg market could disrupt oper downsid risk valuat forecast risk could
countri region specif could also impact rgen strategi creat higher barrier entri exist
futur market local product reagent prefer import synergi may
go plan rgen acquisit still sizabl given profil acquisit may go plan
could result integr risk lower-than-expect synergi integr requir cultur
process adapt synergi model forecast risk estim remain integr
unquantifi aspect target forecast model margin eros could
occur under-perform acquisit larger competitor could also bundl product tri drive
adopt product via bundl potenti impact rgen revenu though rgen
product might innov market lower cost could drive custom shift larger
manufactur bioprocess tool custom highli depend
thousand except share data
royalti revenu
cost expens
product revenu
research develop
research develop
incom incom tax
cost expens
product revenu
research develop
compani report svb leerink estim
